Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Figures & data

Table 1 Comparison of cetuximab and panitumumab

	Cetuximab	Panitumumab
Molecular weight	152.1 kDa	147 kDa
% Murine	34%	0%
Kd EGFR	3.4 × 10^−10	5 × 10^−11
Half-life	∼112 hours	∼180 hours
Grade ¾ hypersensitivity	3%	1%

Table 2 Monoclonal antibody nomenclature (Guidelines on the Use of INNs 1997)

	Target		Source	Suffix
-co(l)-	colonic tumor	-u-	human
-me(l)-	melanoma	-o-	mouse
-ma(r)-	mammary tumor	-a-	rat
-go(t)-	testicular tumor	-e-	hamster	-mab
-go(v)-	ovarian tumor	-i-	primate
-pr(o)-	prostate tumor	-xi-	chimeric
-tu(m)-	miscellaneous tumor	-zu-	humanized

Example: Ce-tu-xi-mab – tumor – chimeric

Pani-tum-u-mab – tumor – human.

Guidelines on the Use of International Nonproprietary Names (INNs) for Pharmaceutical Substances1997World Health Organization [online]2728 URL: http://whqlibdoc.who.int/hq/1997/WHO_PHARM_S_NOM_1570.pdf

 Google Scholar